BiomX (PHGE)
NYSE MKT:PHGE
US Market

BiomX (PHGE) Stock Price & Analysis

324 Followers

PHGE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.13 - $1.17
Previous Close$0.3
Volume112.42K
Average Volume (3M)262.22K
Market Cap
$13.80M
Enterprise Value$2.27M
Total Cash (Recent Filing)$30.30M
Total Debt (Recent Filing)$18.78M
Price to Earnings (P/E)-0.3
Beta1.42
Aug 16, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding45,979,730
10 Day Avg. Volume333,613
30 Day Avg. Volume262,216
Standard Deviation0.23
R-Squared0.10
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.94
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.10
Forecast
Price Target Upside2187.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

PHGE FAQ

What was BiomX’s price range in the past 12 months?
BiomX lowest stock price was $0.13 and its highest was $1.17 in the past 12 months.
    What is BiomX’s market cap?
    Currently, no data Available
    When is BiomX’s upcoming earnings report date?
    BiomX’s upcoming earnings report date is Aug 16, 2023 which is in 77 days.
      How were BiomX’s earnings last quarter?
      BiomX released its earnings results on May 15, 2023. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.175 by -$0.025.
        Is BiomX overvalued?
        According to Wall Street analysts BiomX’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does BiomX pay dividends?
          BiomX does not currently pay dividends.
          What is BiomX’s EPS estimate?
          BiomX’s EPS estimate is -$0.12.
            How many shares outstanding does BiomX have?
            BiomX has 45,979,730 shares outstanding.
              What happened to BiomX’s price movement after its last earnings report?
              BiomX reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.175. Following the earnings report the stock price went up 7.143%.
                Which hedge fund is a major shareholder of BiomX?
                Among the largest hedge funds holding BiomX’s share is Royce & Associates LLC. It holds BiomX’s shares valued at N/A.

                  ---

                  BiomX Stock Smart Score

                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  BiomX

                  BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Neurosense Therapeutics Ltd.
                  Entera Bio
                  ViewBix
                  Vascular Biogenics

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis